Shanghai Bio-heart Biological Technology Co LtdHKG 2185 Stock Report

Shanghai Bio-Heart Biological Technology Co., Ltd. engages in the development of cardiovascular devices. The company is headquartered in Shanghai, Shanghai and currently employs 52 full-time employees. The company went IPO on 2021-12-23. The firm's main businesses are the development and production of interventional cardiovascular devices. The firm's main products include fully bioresorbable scaffolds (BRS) and renal denervation (RDN). The firm's products are mainly used to meet medical needs for the treatment of coronary, peripheral artery disease and hypertension.